Bristol Myers, Exelixis announce Opdivo in combo with Cabometyx shows durable survival with over 3 years of follow-up in CheckMate -9ER trial in first-line advanced RCC

Cobertura de los medios

• Nombre	Bristol Myers, Exelixis announce Opdivo in combo with Cabometyx shows durable survival with over 3 years of follow-up in CheckMate -9ER trial in first-line advanced RCC
  Nombre/canal del medio de comunicación	PharmaBiz
  País/Territorio	India
  Fecha	15/02/23
  URL	ct.moreover.com/?a=50013985520&p=1gw&v=1&x=7K2NQMd_fgfZtLu7XbiMng
  Personas	Mauricio Burotto